Biomarin Pharmaceutical: Here’s What Investors Need to Know Before Earnings

Biomarin Pharmaceutical (NASDAQ:BMRN) will report earnings after markets close on Thursday, July 25th. BioMarin Pharmaceutical Inc. develops and commercializes therapeutic enzyme products. The Company has applied its proprietary enzyme technology to develop products for lysosomal storage diseases and for the treatment of serious burns. BioMarin’s subsidiary provides analytical and diagnostic products and services in the area of carbohydrate biology.

Here is your Cheat Sheet to Biomarin Pharmaceutical Earnings:

Earnings Expectations: Analysts expect earnings of $-0.29 per share on revenues of $134.33 million.

Analyst Trends:

Analysts have a more positive outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has risen from a loss of $0.34 to a loss $0.33. For the current year, the average estimate is a loss of $1.31, which is worse than the estimate ninety days ago.

Earnings Trends:

Here’s how Biomarin Pharmaceutical has been performing on an annual basis:

Fiscal Year 2008 2009 2010 2011 2012
Revenue ($) in millions 296 325 376 441 501
Diluted EPS ($) 0.29 0.00 1.64 -0.48 -0.95

Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:

Quarter Jun. 30, 2012 Sep. 30, 2012 Dec. 31, 2012 Mar. 31, 2013
Revenue ($) in millions 124.02 128.12 131.94 127.93
Diluted EPS ($) -0.27 -0.04 -0.43 -0.31

Past Performance:
Biomarin Pharmaceutical has missed analyst estimates 3 times in the past four quarters. Shareholders could expect a bust if the company misses estimates.

“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at]